More than half a million bottles of prazosin hydrochloride are included in the recall.

WASHINGTON — Nearly 581,000 bottles of a medication used to treat high blood pressure have been recalled after tests revealed potentially cancer-causing chemicals above acceptable safety limits.

Teva Pharmaceuticals issued a voluntary recall for prazosin hydrochloride capsules Oct. 7. It was classified by the FDA as Class II risk level on Oct. 24, which indicates that use of or exposure to the product “may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

The recall affects three dosage strengths of the drug distributed nationwide. While the drug is primarily used to treat high blood pressure and prostate conditions, it is sometimes prescribed off-label to help post-traumatic stress disorder symptoms.

The recalled capsules contain elevated levels of N-nitroso prazosin impurity, according to the FDA report. 


Recalled medications

1 mg capsules: 181,659 bottles (NDC 0093-4067-01 and 0093-4067-10) with lot numbers 3010544A and 3010545A, expiring in October 2025.2 mg capsules: 291,512 bottles (NDC 0093-4068-01 and 0093-4068-10) across multiple lot numbers with expiration dates ranging from October 2025 through July 2026.5 mg capsules: 107,673 bottles (NDC 0093-4069-01, 0093-4069-52, and 0093-4069-05) across multiple lot numbers with expiration dates extending into 2026.


What patients should do

Patients taking the recalled medication should consult their healthcare provider as soon as possible, as suddenly discontinuing blood pressure medication can pose health risks.

The company has notified customers by letter and the recall remains ongoing. Patients with questions about the recall should contact their pharmacist or healthcare provider to determine whether their medication is affected and discuss alternative treatment options.